$55.00
1.20% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US87650L1035
Symbol
TARS
Sector
Industry

Tarsus Pharmaceuticals Inc Stock price

$55.00
+4.16 8.18% 1M
+29.83 118.51% 6M
+34.75 171.60% YTD
+34.53 168.69% 1Y
+29.48 115.52% 3Y
+39.00 243.75% 5Y
+39.00 243.75% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.65 1.20%
ISIN
US87650L1035
Symbol
TARS
Sector
Industry

Key metrics

Market capitalization $2.10b
Enterprise Value $1.86b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 14.33
P/S ratio (TTM) P/S ratio 16.22
P/B ratio (TTM) P/B ratio 8.85
Revenue growth (TTM) Revenue growth 801.96%
Revenue (TTM) Revenue $129.62m
EBIT (operating result TTM) EBIT $-140.60m
Free Cash Flow (TTM) Free Cash Flow $-101.68m
Cash position $316.95m
EPS (TTM) EPS $-3.81
P/E forward negative
P/S forward 12.08
EV/Sales forward 10.67
Short interest 19.47%
Show more

Is Tarsus Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Tarsus Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Tarsus Pharmaceuticals Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Tarsus Pharmaceuticals Inc forecast:

Buy
90%
Hold
10%

Financial data from Tarsus Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
130 130
802% 802%
100%
- Direct Costs 9.12 9.12
430% 430%
7%
121 121
853% 853%
93%
- Selling and Administrative Expenses 210 210
169% 169%
162%
- Research and Development Expense 50 50
6% 6%
38%
-139 -139
24% 24%
-108%
- Depreciation and Amortization 1.16 1.16
0% 0%
1%
EBIT (Operating Income) EBIT -141 -141
24% 24%
-108%
Net Profit -134 -134
25% 25%
-104%

In millions USD.

Don't miss a Thing! We will send you all news about Tarsus Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tarsus Pharmaceuticals Inc Stock News

Positive
Investors Business Daily
3 days ago
Tarsus Pharmaceuticals drew its inspiration from animal-health drugs. Now, the biotech stock is on a triple-digit run.
Positive
Seeking Alpha
13 days ago
Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics.
Neutral
Seeking Alpha
about 2 months ago
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants David Nakasone - Head, IR Bobby Azamian - Chairman & CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - CFO and CSO Sesha Neervannan - COO Elizabeth Yeu - Chief Medical Officer Conference Call Participants Eddie Hickman - Guggenheim Securities Lachlan Hanbury-B...
More Tarsus Pharmaceuticals Inc News

Company Profile

Tarsus Pharmaceuticals, Inc. develops and manufactures drug treatments for Blepharitis. The company focuses on treatment of Blepharitis, which is a common ocular condition, characterized by inflammation of the eyelid, which can impact the anterior or posterior lid or both. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Head office United States
CEO Bobak Azamian
Employees 244
Founded 2017
Website tarsusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today